Close menu




September 30th, 2025 | 07:00 CEST

What is happening at Gerresheimer? Almonty Industries and Rheinmetall are booming again!

  • Mining
  • Tungsten
  • Defense
  • Pharma
Photo credits: pixabay.com

In uncertain times, the focus shifts to companies that form the backbone of our critical infrastructure. Their ability to build resilient and transparent supply chains for essential goods determines our collective resilience to geopolitical and economic upheavals. Where the highest quality and safety standards prevail in areas such as pharmaceuticals, high tech, and defense, sustainable and ethical conduct becomes a decisive competitive advantage, while strict traceability along the value chain becomes the new benchmark. This development makes values such as those of Gerresheimer, Almonty Industries, and Rheinmetall particularly interesting.

time to read: 5 minutes | Author: Armin Schulz
ISIN: GERRESHEIMER AG | DE000A0LD6E6 , ALMONTY INDUSTRIES INC. | CA0203987072 , RHEINMETALL AG | DE0007030009

Table of contents:


    Gerresheimer – Between systemic strength and acute BaFin concerns

    Gerresheimer has long since moved away from being a pure packaging manufacturer. The Company now supplies solutions such as insulin pens and special vials for cancer drugs for the pharmaceutical and biotech industries. The advantage here is the packaging, which not only protects the active ingredients but also enables precise dosing. It is precisely this role in sensitive value chains that makes the Company so important. The global healthcare market is growing steadily, driven by demographic change and the increase in chronic diseases.

    However, this strategic positioning is currently overshadowed by considerable uncertainty. BaFin is auditing the 2024 annual financial statements, specifically the booking of revenues from so-called bill-and-hold agreements. The question arises as to whether revenues may have been booked before the actual delivery. It is important to note in this context that the dispute involves an amount in the low double-digit million range - less than 1% of total revenue. The mere announcement of the audit has severely shaken investor confidence and led to massive share price losses. The real concern is not so much the financial impact as the potential damage to the Company's reputation.

    Despite the acute uncertainty, the medium-term fundamentals remain intact. Management is sticking to its ambitious targets, including annual revenue growth of 6–9%. The recent acquisition of Bormioli Pharma strengthens the portfolio in the promising biopharmaceutical systems segment. For investors, the question is whether the current valuations offer an opportunity to enter a fundamentally healthy business model, or whether governance concerns and a potentially lengthy audit will continue to hold back recovery. The coming quarters will set the course. The share is currently trading at EUR 35.54.

    Almonty Industries – Unique in the Western world

    Almonty Industries has long been a familiar name to investors who focus on critical raw materials. The Company's tungsten serves essential value chains in key sectors. Due to its hardness and heat resistance, this metallic raw material is indispensable for the defense industry, from armor to guidance systems. The aerospace, semiconductor, and electromobility industries also rely on this critical raw material. Almonty's role as a supplier from politically stable regions is gaining additional strategic importance against the backdrop of tense trade relations and dependence on China.

    On September 23, the Company attracted attention with an important operational announcement. It launched a large-scale drilling program at its Sangdong site in South Korea, this time focusing on molybdenum. This metal, whose price is also performing well, improves the heat resistance of alloys and is in demand for future technologies. The drilling is intended to provide data to update the technical report and start production as quickly as possible. The urgency is underscored by supply bottlenecks in South Korea, which highlights the potential significance of the project for regional raw material security. A corresponding purchase agreement with a South Korean SpaceX supplier, including a minimum price, is already in place.

    Almonty received significant external recognition in early September. The Company was included in the Toronto Stock Exchange's TSX30 ranking, which lists the 30 best growth stocks of the last three years. This honor reflects the Company's successful transformation, including its recent Nasdaq listing and the progress made on its flagship Sangdong project. Together with strategic off-take agreements and political recognition of its role in strengthening supply chains, this underscores a long-term growth narrative that extends beyond pure tungsten production. It is therefore not surprising that the stock is trading near its all-time high and is currently available on the NASDAQ at USD 5.93.

    To learn more, register ii-forum.com/speaker/lewis-black-ceo-almonty-industries-inc for free for the upcoming virtual International Investment Forum (IIF) taking place on October 8, 2025.

    Rheinmetall – The backbone of European defense

    Rheinmetall positions itself as much more than just an arms manufacturer. The Company is a strategic architect of essential value chains that are indispensable for national and European security. Its influence ranges from the procurement of critical raw materials such as rare earths and antimony, which are indispensable for high-tech weapon systems and ammunition, to the development of complete defense systems. In order to break away from global dependencies, especially on China, the group is systematically establishing alternative sources of supply, thereby securing long-term delivery capabilities. This control over the entire chain, from material procurement to logistics, makes Rheinmetall a fundamental pillar of the defense infrastructure.

    In September, Rheinmetall stepped on the gas again and reinforced its expansion strategy with a real bang. The Company snapped up the NVL marine division from the Lürssen Group, including the legendary Blohm+Voss shipyard. Provided the antitrust authorities give the green light, the deal is expected to go through in early 2026. This move marks the DAX giant's entry into shipbuilding. Suddenly, the pure land systems specialist has become a cross-domain systems provider, now sailing in entirely new waters. The integration of NVL creates a German powerhouse for surface vessels and opens up completely new business areas in the maritime sector.

    Parallel to its entry into the naval sector, Rheinmetall is pushing ahead with internationalization. The list of major projects also includes the construction of a new ammunition factory in Latvia, which is planned as a joint venture. From 2026, the plant, which will cost around EUR 275 million, is expected to produce tens of thousands of artillery shells every year. This will not only strengthen the Baltic states' defense capabilities, but also enable Rheinmetall to significantly expand its global production network. Together with the planned projects in the US and other European countries, the group is underlining its growing role: it is increasingly becoming the central guarantor for the supply of ammunition technology to NATO partners. Rheinmetall's share price is once again approaching the EUR 2,000 mark and is currently trading at EUR 1,995.00.


    In uncertain times, companies with critical supply chains prove their worth. Gerresheimer, despite an ongoing BaFin audit, continues to provide system-relevant pharmaceutical solutions with an apparently intact business model. Almonty Industries is solidifying its role as a strategic supplier of rare metals and driving forward its expansion through a new drilling program. Rheinmetall, meanwhile, is increasingly shaping itself into an indispensable, cross-domain system house for European defense through acquisitions such as NVL. Their common denominator is resilience, which is becoming increasingly important today.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST

    AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk

    • AI
    • Biotechnology
    • Biotech
    • Pharma

    Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!

    Read

    Commented by Carsten Mainitz on October 21st, 2025 | 07:40 CEST

    Power Metallic Mines, RENK, BYD – An explosive combination! And the winners are?

    • Mining
    • Copper
    • Nickel
    • Gold
    • CriticalMetals
    • Electromobility
    • Defense

    Many topics are dominating the headlines. Peace in Gaza – and soon in Ukraine? This prospect initially put a significant damper on defense stocks – but only temporarily. After just a few days of correction, prices are already rising again. Gold at an all-time high is another major topic being covered in the media. Meanwhile, the geopolitical shifts we were reluctant to acknowledge for far too long are now catching up with many companies: China is cutting the world off from critical raw materials and rare earths. Read here to find out how investors can identify promising high-potential opportunities in this constellation.

    Read

    Commented by André Will-Laudien on October 21st, 2025 | 07:35 CEST

    Gold USD 4,300 and Silver USD 53 – Buying frenzy at Silver North, First Majestic, Nel ASA, and JinkoSolar

    • Mining
    • Silver
    • Gold
    • renewableenergies
    • Solar
    • Energy

    Silver has been shorted by many investment banks for several years because sufficient supply was available from Mexico and other producing countries. The tide has turned. Over the past 12 months, the precious metal has caught up with its big brother gold, gaining 54%. There are several reasons for the scarcity-driven rally: there are only around 250 active silver mines worldwide, compared to around 1,400 gold mines. In addition, silver has massively expanded its importance as an industrial metal: it is indispensable in high-tech, e-mobility, defense, and medical technology. As a result, less and less physical silver is available to investors, while inventories on the futures markets continue to decline. Now is the time to take a position in silver. Alongside industry giants such as First Majestic, Silver North is among the most promising beneficiaries of the new silver boom.

    Read